Pancreatic Cancer Research

ResearcherAzienda Ospedaliera Sant'AndreaActive in the last 2 years

Giovanni Ramacciato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4612-9507; OpenAlex author ID A5022172602. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 13)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 18

  1. Association of TP53 Arg72Pro (rs1042522) Polymorphism with Pancreatic Cancer Risk in a Patient Cohort Co-author DOI 10.3390/onco5040044↗
  2. Correction to: Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies. Last author DOI 10.1007/s11605-021-05190-z↗
  3. Is Complete Pathologic Response in Pancreatic Cancer Overestimated? A Systematic Review of Prospective Studies. Last author DOI 10.1007/s11605-020-04697-1↗
  4. Corrigendum to "Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancrea… Last author DOI 10.1016/j.ijsu.2019.05.015↗
  5. Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcin… Last author DOI 10.1097/sla.0000000000003372↗
  6. Evolution of pancreatectomy with en bloc venous resection for pancreatic cancer in Italy. Retrospective cohort study on 425 cases in 10 pancreatic referral uni… Last author DOI 10.1016/j.ijsu.2018.05.025↗
  7. Can pancreatic cancer be detected by adrenomedullin in patients with new-onset diabetes? The PaCANOD cohort study protocol. Co-author DOI 10.5301/tj.5000693↗
  8. Neoadjuvant treatment in pancreatic cancer: Evidence-based medicine? A systematic review and meta-analysis. Last author DOI 10.1007/s12032-017-0951-0↗
  9. Borderline resectable pancreatic cancer: an evolving concept. Last author DOI 10.1093/annonc/mdx255↗
  10. Prognostic role of nodal ratio, LODDS, pN in patients with pancreatic cancer with venous involvement. Co-author DOI 10.1186/s12893-017-0311-1↗
  11. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials. Last author DOI 10.1007/s12032-016-0742-z↗
  12. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients. Co-author DOI 10.1245/s10434-016-5123-5↗
  13. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph… Last author DOI 10.1016/j.pan.2014.05.794↗
  14. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Last author DOI 10.5009/gnl.2014.8.1.102↗
  15. Standard retrograde pancreatosplenectomy versus radical antegrade modular pancreatosplenectomy for body and tail pancreatic adenocarcinoma. Last author DOI 10.1177/000313481307901117↗
  16. Hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Last author DOI 10.1177/000313481207800243↗
  17. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Last author DOI 10.1245/s10434-012-2348-9↗
  18. Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. Co-author DOI 10.1002/jso.22013↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Niccolò Petrucciani · 12 shared papers, 2014–2025 · strength 1.11
  2. Giuseppe R. Nigri · 15 shared papers, 2011–2025 · strength 1.09
  3. Laura Antolino · 7 shared papers, 2016–2025 · strength 0.81
  4. Francesco D’Angelo · 6 shared papers, 2016–2025 · strength 0.65
  5. Elio Jovine · 4 shared papers, 2016–2019 · strength 0.26
  6. Francesco Minni · 4 shared papers, 2016–2019 · strength 0.26
  7. Niccolò Napoli · 4 shared papers, 2016–2019 · strength 0.26
  8. Ugo Boggi · 4 shared papers, 2016–2019 · strength 0.26
  9. Antonio Daniele Pinna · 4 shared papers, 2016–2019 · strength 0.26
  10. Marco La Torre · 6 shared papers, 2011–2014 · strength 0.23
  11. Germana de Nucci · 1 shared paper, 2025 · strength 0.21
  12. Gianpiero Manes · 1 shared paper, 2025 · strength 0.21
  13. Vincenzo Ziparo · 5 shared papers, 2011–2014 · strength 0.19
  14. Gianpaolo Balzano · 2 shared papers, 2018–2019 · strength 0.15
  15. Genoveffa Balducci Md · 2 shared papers, 2013–2014 · strength 0.09
  16. Jean GUGENHEIM MD3 · 1 shared paper, 2017 · strength 0.08
  17. Paolo Marchetti · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.